Therapure launches IPO to grow biologics contracting business

By Dan Stanton contact

- Last updated on GMT

Photo - pichet_w/iStock
Photo - pichet_w/iStock

Related tags: Investment

Therapure Biopharma Inc. plans to go public to fund the expansion of its manufacturing facility and CMO business.

A preliminary prospectus filed with Canadian Securities Regulators​ last week states that Therapure aims to raise funds “for plant expansion" ​and the development of its therapeutic biologics business.

Therapure's 130,000 sq ft facility in Toronto makes intraveneous immunoglobulin (IVIG) and albumin-based therapies for both its own pipeline as well as for drug industry customers.

The site has seen a number of investments in equipment and additional clean room space since the firm was set up in 2008 by Canadian private equity fund Catalyst Capital Group, as well as C$17m ($13m) worth of investment from its clients.

“Therapure has invested and will continue to invest in the capacity to add commercial scale capabilities,”​ the company says in its prospectus.

“Sustaining the infrastructure to produce biologics is a strong motivating factor for biotech companies to seek Therapure’s CDMO services due to the long lead times, regulatory hurdles and costs to develop their own facilities.

“The replacement cost of Therapure’s facility (including land value) is estimated at $180m [$135m] and would take a minimum of three to four years to reconstruct.”

CDMO Growth

Therapure claims it has seen a CAGR of around 50% since 2010.

Several top ten big pharma clients on its books, as well as a number of mid-sized pharma and biotech/emerging pharma companies.

Therapure has an ongoing contract with french firm LFB​ for the manufacture of two plasma proteins, and a long-term “take or pay contract”​ with Insmed – a contributor to the retrofit of one of Therapure’s manufacturing suites - for the manufacture of its cystic fibrosis therapy.

The firm is looking to increase its share of the contract biomanufacturing market, which it estimates to be worth around $4bn, and prides itself on its client retention.

“This client ‘stickiness’ is due to the high costs that would be incurred by a client if it switched to a competitor as measured in both time and money,”​ the company says.

“Management believes that it would take approximately three years and cost around $10 million to effect an established process. Management is not aware of any client having left Therapure for a competitor over the past four years.”

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars